Blood pressure drug therapy and electrolyte disturbances

International Journal of Clinical Practice

Volumn 62, Issue 10, 2008, Pages 1572-1580

  Liamis, G ^a   Milionis, H ^a   Elisaf, M ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL;

BLOOD PRESSURE; ELECTROLYTE DISTURBANCE; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; WATER-ELECTROLYTE IMBALANCE;

EID: 51349105734     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01860.x     Document Type: Review

References (98)

1. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001 345 : 479 86.
2. Krakoff LR. Diuretics for hypertension. Circulation 2005 112 : e127 9.
3. Salvetti A, Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol 2006 17 : S25 9.
4. Padilla MC, Armas-Hernandez MJ, Hernandez RH et al. Update of diuretics in the treatment of hypertension. Am J Ther 2007 14 : 154 60.
5. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004 328 : 634 40.
6. Frishman WH, Alwarshetty M. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 2002 41 : 505 16.
7. Overlack A, Higuchi M, Kolloch R, Stumpe KO. Converting enzyme activity and essential hypertension. Klin Wochenschr 1983 61 : 377 8.
8. Rangoonwala B, Rosenthal I. Management of hypertension and its sequelae with ACE inhibitors: biochemical, pharmacological and clinical aspects. Int J Clin Pract 1998 52 : 492 500.
9. Contreras F, de la Parte MA, Cabrera J et al. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension. Am J Ther 2003 10 : 401 8.
10. Chow KM, Szeto CC, Wong TY et al. Risk factors for thiazide-induced hyponatraemia. QJM 2003 96 : 911 7.
11. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis 2008 52 : 144 53.
12. Spital A. Diuretic-induced hyponatremia. Am J Nephrol 1999 19 : 447 52.
13. Friedman E, Shadel M, Halkin H, Farfel Z. Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann Intern Med 1989 110 : 24 30.
14. Ashraf N, Locksley R, Arieff AI. Thiazide-induced hyponatremia associated with death or neurologic damage in outpatients. Am J Med 1981 70 : 1163 8.
15. Ashouri OS. Severe diuretic-induced hyponatremia in the elderly. A series of eight patients. Arch Intern Med 1986 146 : 1355 7.
16. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993 103 : 601 6.
17. Abramow M, Cogan E. Clinical aspects and pathophysiology of diuretic-induced hyponatremia. Adv Nephrol Necker Hosp 1984 13 : 1 28.
18. Clark BA, Shannon RP, Rosa RM, Epstein FH. Increased susceptibility to thiazide-induced hyponatremia in the elderly. J Am Soc Nephrol 1994 5 : 1106 11.
19. Pinnock CA. Hyponatraemia associated with hydrochlorothiazide treatment. Br Med J 1978 1 : 48.
20. Chapman MD, Hanrahan R, McEwen J, Marley JE. Hyponatraemia and hypokalaemia due to indapamide. Med J Aust 2002 176 : 219 21.
21. Tarssanen L, Huikko M, Rossi M. Amiloride-induced hyponatremia. Acta Med Scand 1980 208 : 491 4.
22. Liamis G, Christidis D, Alexandridis G et al. Uric acid homeostasis in the evaluation of diuretic-induced hyponatremia. J Investig Med 2007 55 : 36 44.
23. Heinemann HO, Demartini FE, Laragh JH. The effect of chlorothiazide on renal excretion of electrolytes and free water. Am J Med 1959 26 : 853 61.
24. Sonnenblick M, Algur N, Rosin A. Thiazide-induced hyponatremia and vasopressin release. Ann Intern Med 1989 110 : 751.
25. Fichman MP, Vorherr H, Kleeman CR, Telfer N. Diuretic-induced hyponatremia. Ann Intern Med 1971 75 : 853 63.
26. Kumar S, Berl T Sodium. Lancet 1998 352 : 220 8.
27. Gross P, Palm C. Thiazides: do they kill? Nephrol Dial Transplant 2005 20 : 2299 301.
28. Hamburger S, Koprivica B, Ellerbeck E, Covinsky JO. Thiazide-induced syndrome of inappropriate secretion of antidiuretic hormone. Time course of resolution. JAMA 1981 246 : 1235 6.
29. Arieff AI. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med 1986 314 : 1529 35.
30. Rabinstein AA, Wijdicks EF. Hyponatremia in critically ill neurological patients. Neurologist 2003 9 : 290 300.
31. Arieff AI, Guisado R. Effects on the central nervous system of hypernatremic and hyponatremic states. Kidney Int 1976 10 : 104 16.
32. Reynolds RM, Seckl JR. Hyponatraemia for the clinical endocrinologist. Clin Endocrinol (Oxf) 2005 63 : 366 74.
33. Verbalis JG, Martinez AJ. Neurological and neuropathological sequelae of correction of chronic hyponatremia. Kidney Int 1991 39 : 1274 82.
34. Ayus JC, Krothapalli RK, Arieff AI. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med 1987 317 : 1190 5.
35. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986 314 : 1535 42.
36. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994 4 : 1522 30.
37. Karp BI, Laureno R. Pontine and extrapontine myelinolysis: a neurologic disorder following rapid correction of hyponatremia. Medicine (Baltimore) 1993 72 : 359 73.
38. Lohr JW. Osmotic demyelination syndrome following correction of hyponatremia: association with hypokalemia. Am J Med 1994 96 : 408 13.
39. Lien YH, Shapiro JI, Chan L. Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis. J Clin Invest 1991 88 : 303 9.
40. Swales JD. Magnesium deficiency and diuretics. Br Med J (Clin Res Ed) 1982 285 : 1377 8.
41. Itescu S, Haskell LP, Tannenberg AM. Thiazide-induced clinically significant hypophosphatemia. Clin Nephrol 1987 27 : 161 2.
42. Plante GE, Lafreniere MC, Tam PT, Sirois P. Effect of indapamide on phosphate metabolism and vascular reactivity. Am J Med 1988 84 : 26 30.
43. Lemann J Jr., Pleuss JA, Gray RW, Hoffmann RG. Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults [corrected]. Kidney Int 1991 39 : 973 83.
44. Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Pathogenetic mechanisms of hypomagnesemia in alcoholic patients. J Trace Elem Med Biol 1995 9 : 210 4.
45. + homeostasis. Semin Nephrol 1987 7 : 253 62.
46. Anderson J, Foster JB. The effect of cortisone on urinary phosphate excretion in man. Clin Sci 1959 18 : 437 9.
47. Wu X, Ackermann U, Sonnenberg H. Potassium depletion and salt-sensitive hypertension in Dahl rats: effect on calcium, magnesium, and phosphate excretions. Clin Exp Hypertens 1995 17 : 989 1008.
48. Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 1977 137 : 203 20.
49. Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000 35 : 1025 30.
50. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 288 : 2981 97.
51. Siegel D, Hulley SB, Black DM et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA 1992 267 : 1083 9.
52. Schnaper HW, Freis ED, Friedman RG et al. Potassium restoration in hypertensive patients made hypokalemic by hydrochlorothiazide. Arch Intern Med 1989 149 : 2677 81.
53. Zillich AJ, Garg J, Basu S et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006 48 : 219 24.
54. Freis ED. The efficacy and safety of diuretics in treating hypertension. Ann Intern Med 1995 122 : 223 6.
55. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 1998 279 : 1813 6.
56. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004 43 : 155 61.
57. Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med 2000 160 : 2429 36.
58. Caralis PV, Materson BJ, Perez-Stable E. Potassium and diuretic-induced ventricular arrhythmias in ambulatory hypertensive patients. Miner Electrolyte Metab 1984 10 : 148 54.
59. Burgess E. Eplerenone in hypertension. Expert Opin Pharmacother 2004 5 : 2573 81.
60. Croom KF, Perry CM. Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs 2005 5 : 51 69.
61. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000 109 : 307 14.
62. Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. Arch Intern Med 1987 147 : 867 9.
63. McNay JL, Oran E. Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870). Metabolism 1970 19 : 58 70.
64. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 49 : 839 45.
65. Dharmarajan TS, Nguyen T, Russell RO. Life-threatening, preventable hyperkalemia in a nursing home resident: case report and literature review. J Am Med Dir Assoc 2005 6 : 400 5.
66. Castellino P, Simonson DC, DeFronzo RA. Adrenergic modulation of potassium metabolism during exercise in normal and diabetic humans. Am J Physiol 1987 252 : E68 76.
67. Lim M, Linton RA, Wolff CB, Band DM. Propranolol, exercise, and arterial plasma potassium. Lancet 1981 2 : 591.
68. Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol 1990 33 : 269 71.
69. Nowicki M, Miszczak-Kuban J. Nonselective beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron 2002 91 : 222 7.
70. Nowicki M, Szewczyk-Seifert G, Klimek D, Kokot F. Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. Clin Nephrol 2002 57 : 352 8.
71. Aggarwal A, Wong J, Campbell DJ. Carvedilol reduces aldosterone release in systolic heart failure. Heart Lung Circ 2006 15 : 306 9.
72. Saito M, Nakayama D, Takada M et al. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil. J Clin Pharm Ther 2006 31 : 535 40.
73. Lowenthal DT, Affrime MB, Falkner B et al. Potassium disposition and neuroendocrine effects of propranolol, methyldopa and clonidine during dynamic exercise. Clin Exp Hypertens A 1982 4 : 1895 911.
74. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998 158 : 917 24.
75. Ahuja TS, Freeman D Jr., Mahnken JD et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000 20 : 268 72.
76. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004 351 : 585 92.
77. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998 158 : 26 32.
78. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995 75 : 793 5.
79. DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980 17 : 118 34.
80. Arruda JA, Batlle DC, Sehy JT et al. Hyperkalemia and renal insufficiency: role of selective aldosterone deficiency and tubular unresponsiveness to aldosterone. Am J Nephrol 1981 1 : 160 7.
81. Bakris GL, Siomos M, Richardson D et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 2000 58 : 2084 92.
82. Phillips CO, Kashani A, Ko DK et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007 167 : 1930 6.
83. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004 351 : 543 51.
84. Lam S, Choy M. Aliskiren: an oral renin inhibitor for the treatment of hypertension. Cardiol Rev 2007 15 : 316 23.
85. Quamme GA. Renal magnesium handling: new insights in understanding old problems. Kidney Int 1997 52 : 1180 95.
86. Ryan MP. Diuretics and potassium/magnesium depletion. Directions for treatment. Am J Med 1987 82 : 38 47.
87. Durlach J, Bac P, Durlach V et al. Magnesium status and ageing: an update. Magnes Res 1998 11 : 25 42.
88. Wester PO. Electrolyte balance in heart failure and the role for magnesium ions. Am J Cardiol 1992 70 : 44C 9C.
89. Ryan MP, Devane J, Ryan MF, Counihan TB. Effects of diuretics on the renal handling of magnesium. Drugs 1984 28 (Suppl. 1 167 81.
90. Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Saf 2005 28 : 763 88.
91. Whang R, Whang DD, Ryan MP. Refractory potassium repletion. A consequence of magnesium deficiency. Arch Intern Med 1992 152 : 40 5.
92. Lemann J Jr., Gray RW, Maierhofer WJ, Cheung HS. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int 1985 28 : 951 8.
93. Costanzo LS, Windhager EE. Calcium and sodium transport by the distal convoluted tubule of the rat. Am J Physiol 1978 235 : F492 506.
94. Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician 2003 67 : 1959 66.
95. Christensson T, Hellstrom K, Wengle B. Hypercalcemia and primary hyperparathyroidism. Prevalence in patients receiving thiazides as detected in a health screen. Arch Intern Med 1977 137 : 1138 42.
96. Costanzo LS. Localization of diuretic action in microperfused rat distal tubules: Ca and Na transport. Am J Physiol 1985 248 : F527 35.
97. 2+ absorption in rabbit CNT. Am J Physiol 1991 261 : F36 43.
98. Friedman PA, Gesek FA. Stimulation of calcium transport by amiloride in mouse distal convoluted tubule cells. Kidney Int 1995 48 : 1427 34.